M.D. (2001), Ph.D. (2007), HDR (2013)
2012-2013 : Post-doctoral fellowship, (Dr. Anne Lenaerts, Colorado State University, Fort Collins, Colorado, United States)
Positions and Employment
2001-2007 : Lecturer in Bacteriology, Pitié-Salpêtrière school of Medecine, University Pierre et Marie Curie, Paris, France and resident at Hospital Pitié-Salpêrière, Assistance publique-Hospital of Paris (AP-HP)
2007 to present : Assistant Professor in Bacteriology, Pitié-Salpêtrière school of Medecine, Université Pierre et Marie Curie, and staff medical microbiologist at Hospital Pitié-Salpêtrière, Assistance publique-Hospital of Paris (AP-HP)
Other Experience and Professional Memberships
Senior researcher in the research team, “Emergence and diffusion of Multiple Resistance against Antibiotics ", Centre d’Immunologie et des Maladies Infectieuses, INSERM U1135, University Pierre et Marie Curie, 2001 to present.
Member of the French National Reference Laboratory for Mycobacteria and Drug Resistance, 2001 to present.
My ressearch is focused on the treatment of mycobacterial infections. I started during my DEA dealing with the treatment of MDR-TB in the mouse model. Since then, I extended my thinking on this subject by my dual clinical and biological activity within the National Reference Center for Mycobacteria. The topics that I wanted to study are a natural extension of questions that emerge during my daily hospital practice, especially in my therapeutic consultancy of difficult to treat mycobacterila infections. I have until now mainly conducted a research activity on experimental chemotherapy of tuberculosis evaluating new drugs as Bedaquiline or new ways to use existing drugs as fluoroquinolones. Meanwhile I have conducted studies on the epidemiology of TB drug resistance mechanisms. Finally, I have also evaluated the activity of anti-mycobacterial drugs against the emerging pathogen Mycobacterium abscessus. Finally, my therapeutic consultancy led me to be associated with several clinical research projects, particularly in the treatment of MDR tuberculosis.